PeptidePedia The community reference

Contributions of ArcuateArt

User contributions·26 logged edits·page 1 of 1

Contributions by ArcuateArt, newest first. This list covers edits recorded in the site's change log; the editor's lifetime total of 5,744 edits includes activity predating the current log.

  1. 20:55, 19 Jul 2026 (diff | hist) Albumin binding half-life extension 6,399 ±0 rm the sentence implying the hormone is a drug
  2. 21:09, 30 Jun 2026 (diff | hist) Qingdao Saber Technology Pharmaceutical 14,592 ±0 m add the research-use-only statement to the lead rather than only the footer
  3. 11:27, 17 Jun 2026 (diff | hist) Wuhan Wansheng Biotechnology 15,849 ±0 fix the anchor on an internal link
  4. 07:17, 15 Jun 2026 (diff | hist) Beta cell function 6,096 ±0 m add the reference range with the assay it was established on
  5. 12:15, 25 May 2026 (diff | hist) Talk:Satiety signalling 885 +218 /* Decerebrate preparations */ reply
  6. 00:29, 2 May 2026 (diff | hist) Enteroendocrine L cell 5,083 ±0 m add a figure for the secretion time course and caption it
  7. 02:29, 23 Apr 2026 (diff | hist) Dose escalation schedule 4,993 ±0 state that swirling rather than shaking is the handling convention, sourced
  8. 15:25, 14 Apr 2026 (diff | hist) Talk:Arcuate nucleus 748 +215 /* How much animal work should be cited as though it were human? */ reply
  9. 18:44, 24 Mar 2026 (diff | hist) Chinese Peptide Company 15,513 ±0 expand §Corporate identity and history
  10. 15:00, 19 Mar 2026 (diff | hist) Talk:Satiety signalling 748 +215 /* Energy expenditure claim */ reply
  11. 13:50, 28 Feb 2026 (diff | hist) Talk:Arcuate nucleus 611 +171 /* Inverse agonism at MC4R */ reply
  12. 17:14, 23 Dec 2025 (diff | hist) Electrospray ionisation 4,323 ±0 clarify the difference between related substances and total impurities
  13. 13:55, 19 Dec 2025 (diff | hist) Glucagon-like peptide-1 12,294 ±0 convert the receptor-distribution list to a table
  14. 07:11, 14 Dec 2025 (diff | hist) Dulaglutide 5,490 ±0 move the trade-name history out of the lead and into §Regulatory history
  15. 15:01, 20 Nov 2025 (diff | hist) Arcuate nucleus 5,251 ±0 typo
  16. 21:10, 10 Aug 2025 (diff | hist) Satiety signalling 5,593 +348 m add see also to the sister hormone
  17. 17:13, 5 Aug 2025 (diff | hist) Melanotan II 4,374 +650 m British spelling per PP:MOS
  18. 03:49, 24 Jul 2025 (diff | hist) GLP-1 receptor 7,570 +421 m add see also to the sister hormone
  19. 06:43, 18 Jul 2025 (diff | hist) Aspiration risk under anaesthesia 4,377 ±0 correct the percentage — source reports it per patient-year
  20. 08:49, 12 Jun 2025 (diff | hist) Proglucagon 6,144 +401 add short description
  21. 16:24, 15 Jan 2025 (diff | hist) Mass spectrometry 4,327 ±0 correct the resolution formula — the denominator is the sum of the widths
  22. 00:32, 6 Jan 2025 (diff | hist) Insulin secretion 4,555 +109 expand §Pulsatility and measurement
  23. 23:06, 23 Dec 2024 (diff | hist) Glucose-dependent insulinotropic polypeptide 6,231 +654 expand §Biosynthesis and secretion
  24. 11:31, 3 Nov 2024 (diff | hist) Insulin secretion 3,940 ±0 m distinguish the active and total forms of the hormone throughout
  25. 21:57, 17 Sep 2024 (diff | hist) GLP-1 receptor 3,867 +153 m split §Physiology from §Pharmacological exploitation
  26. 12:48, 16 Aug 2024 (diff | hist) Dipeptidyl peptidase-4 3,295 +240 expand §Analytical relevance